Triple-Drug combo aims to improve diabetes control and weight loss

NCT ID NCT07139405

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This study tests a new combination drug called TriGlytza-01 in overweight adults with type 2 diabetes whose blood sugar is not well controlled by metformin alone. The trial compares TriGlytza-01 to standard metformin over 16 weeks, measuring safety, blood sugar levels, and body weight. Participants are randomly assigned to one of three groups and take daily pills. The goal is to see if this triple-drug approach can offer better diabetes management.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
TriGlytza-01 (a combination of metformin, celecoxib, and valsartan)
What this could lead to
If successful, this could offer a new combination treatment option for people with type 2 diabetes who need better blood sugar control and weight management.
What could go wrong
This is an early Phase 2a trial with only 48 participants, so results may not apply to everyone. The combination includes drugs with known side effects, and it may not prove more effective than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES (T2DM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Momentum Darlinghurst

    Sydney, Australia

  • Momentum Sunshine

    Melbourne, Victoria, Australia

  • UniSC Clinical Trials

    Maroochydore, Queensland, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.